Background

Developing novel therapies for rare and ultra-rare diseases has consistently faced significant hurdles. Due to the inherent characteristics of these diseases, the number of patients is extremely limited, making it virtually impossible to conduct traditional randomized controlled trials (RCTs) that require hundreds or thousands of participants. Existing regulatory systems rely on statistical significance derived from large patient populations as the basis for approval. Consequently, therapies for ultra-rare diseases, where the patient population may be only a few dozen, often face challenges in demonstrating efficacy and may be discontinued during development or fail to meet the approval threshold. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has sought innovative solutions to overcome these regulatory limitations. This initiative aims to provide patients with timely access to treatment options while ensuring the safety and efficacy of these therapies through a flexible regulatory framework.

Key Findings

The MHRA's recently released draft of the 'Rare Disease Therapies Regulatory Framework' represents a significant departure from traditional regulatory approaches. The core of this revision is the introduction of the 'Investigational Marketing Authorisation (IMA)' system, which integrates the clinical trial approval stage and the marketing authorization pathway into a single process. This system targets therapies for ultra-rare diseases, defined as those affecting fewer than one in 50,000 individuals. Drugs entering the IMA pathway can receive conditional marketing authorization based on preclinical data and limited but compelling efficacy data from early clinical trials. Following approval, the developer must continuously collect and submit real-world evidence (RWE) and biomarker-based data gathered during patient treatment to the regulatory agency. The MHRA will then conduct a phased, modular review to comprehensively evaluate safety and efficacy, gradually refining the approval. This approach also incorporates the characteristics of advanced therapy medicinal products (ATMPs) and personalized gene therapies, reflecting the evolving landscape of biotechnology. The MHRA's proposal demonstrates a commitment to addressing the urgency of these diseases and adapting to the unique technical aspects of novel therapies, moving away from a one-size-fits-all approach.

Implications and Outlook

This proposal has the potential to serve as a significant benchmark for regulatory agencies worldwide. It aligns with the recent trend of regulatory flexibility, as exemplified by the US Food and Drug Administration (FDA)'s release of the Rare Disease Evidence Principles (RDEP). The MHRA's draft is currently undergoing a public consultation process, with the deadline for comments set for July 30, 2026. However, challenges remain in the implementation phase. Concerns have been raised regarding the potential safety risks associated with releasing drugs onto the market based on limited early clinical data. Furthermore, the infrastructure and financial support required to systematically collect and validate RWE in clinical settings need to be established. Moreover, the formal adoption of the IMA will require legal amendments in the UK, suggesting that the full implementation of this system may take some time.